FDA Resubmission of UX111 and Regulatory Overcoming Process

Ultragenyx Pharmaceutical's gene therapy UX111 (rebisufligene etisparvovec) has once again reached the final gate for FDA approval. After receiving a Complete Response Letter (CRL) in July 2025 due to issues related to Chemistry, Manufacturing, and Controls (CMC) and facility inspection, the company swiftly addressed the concerns and successfully resubmitted the Biologics License Application (BLA) in April 2026. The FDA has formally accepted the resubmission, setting the Prescription Drug User Fee Act (PDUFA) goal date for final decision as September 19, 2026. This resubmission will serve as a critical test of whether the manufacturing issues have been fully resolved, marking the final step before commercialization.

Differentiated Mechanism and Clinical Performance of the scAAV9 Platform Technology

UX111 is a gene therapy based on the self-complementary adeno-associated virus 9 (scAAV9) vector, which directly delivers a functional gene into damaged cells. This technology restores the activity of the sulfamidase (SGSH) enzyme, which is deficient in patients and causes glycosaminoglycan accumulation in the brain and body tissues. Thanks to its innovative vector platform that can cross the central nervous system (CNS) barrier, UX111 provides a differentiated therapeutic effect by preventing cognitive decline with a single intravenous administration. The Transpher A (NCT02716246) global Phase 1/2/3 trial demonstrated clinical improvements in cognitive and language domains, along with a sustained reduction in cerebrospinal fluid heparan sulfate (CSF-HS) levels, confirming its innovation.

Potential for Monopoly in the High-Unmet-Need MPS IIIA Market

Mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo Syndrome A) is a fatal, degenerative, rare genetic disorder affecting approximately 1 in 100,000 newborns, for which there are currently no approved curative treatments. The overall MPS III market is estimated to be worth $1.83 billion in the seven major countries in 2025, with Subtype A accounting for 42.7%, or approximately $780 million. If UX111 is approved as scheduled, it is expected to become the first commercial gene therapy (First-in-Class) in this large untapped market, securing a strong monopoly position. This would generate hundreds of millions in new revenue annually and significantly strengthen Ultragenyx's leadership in the rare disease market.

Collapse of Competitive Pipelines and Establishment of a Differentiated Monopoly

In terms of competitive landscape, Lysogene's LYS-SAF302 (based on AAVrh.10) has withdrawn from the market after failing to meet its primary endpoint in the Phase 2/3 AAVance trial. Meanwhile, Orchard Therapeutics' ex vivo gene therapy OTL-201, which is based on hematopoietic stem cells, remains a potential competitor, having received the UK's Innovation License and Access Pathway (ILAP) Innovation Passport in April 2026. However, OTL-201 requires a complex and time-consuming process of ex vivo gene correction and reinfusion, whereas Ultragenyx's UX111 offers a clear advantage in terms of dosing convenience due to its in vivo administration directly into the body.